3-fluoro-5-isopropylbenzoic acid | 942508-01-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-fluoro-5-isopropylbenzoic acid
• 英文别名: 3-Fluoro-5-(propan-2-yl)benzoic acid；3-fluoro-5-propan-2-ylbenzoic acid
• CAS: 942508-01-2
• 化学式: C₁₀H₁₁FO₂
• 分子量: 182.195
• InChiKey: AYBKUTSZRQMTCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-cyclopropyl-5-fluorobenzoic acid 在 platinum(IV) oxide 氢气 、 溶剂黄146 作用下， 反应 3.0h， 以88%的产率得到3-fluoro-5-isopropylbenzoic acid
  参考文献：
  名称：

  WO2007/71963

  摘要：

  公开号：

文献信息

• [EN] MACROCYCLIC COMPOUNDS AND THEIR USE AS CDK8 INHIBITORS<br/>[FR] COMPOSÉS MACROCYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE CDK8
  申请人：CT NAC INVESTIGACIONES ONCOLOGICAS CNIO

  公开号：WO2013001310A1

  公开（公告）日：2013-01-03

  There is provided compounds of formula I, wherein R1, R2, R3, R4, X, Y, Z and ring A have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

  提供了具有式I的化合物，其中R1、R2、R3、R4、X、Y、Z和环A的含义如描述中所给，并且其药学上可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要或期望抑制蛋白质或脂质激酶（例如CDK8）的疾病中非常有用，特别是在癌症或增生性疾病的治疗中。
• NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
  申请人：Chen Sean

  公开号：US20080021052A1

  公开（公告）日：2008-01-24

  Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; R 1 is aryl or heteroaryl; R 2 is halogen, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 5 is as defined herein; Z is O, S, S(O), S(O)2, or NR 5a ; X is S, O, N, NR 3 , or CR 3 ; Y is NCR 4 or N 4 ; R 3 , R 4 , and R 5 are as defined herein; R 8 is aryl or heteroaryl; R 6 and R 7 are independently H, halogen, or alkyl; m is 0 or 1; and n is 0 to 3, or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

  提供了一种葡萄糖激酶激活剂，因此对治疗糖尿病和相关疾病有用，并具有以下结构：环中表示一个或两个双键；R1是芳基或杂环芳基；R2是卤素、环烷基、杂环烷基、芳基或杂环芳基；R5如本文所定义；Z为O、S、S(O)、S(O)2或NR5a；X为S、O、N、NR3或CR3；Y为NCR4或N4；R3、R4和R5如本文所定义；R8是芳基或杂环芳基；R6和R7独立地为H、卤素或烷基；m为0或1；n为0至3，或其药用盐。还提供了一种利用上述化合物治疗糖尿病和相关疾病的方法。
• Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents
  申请人：Aquila Brian

  公开号：US20080306096A1

  公开（公告）日：2008-12-11

  The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

  本发明涉及化学式(I)或其药学上可接受的盐的化合物，其具有B Raf抑制活性，因此在抗癌活性及人或动物体的治疗方法中有用。本发明还涉及制造上述化学物质的过程，包含它们的制药组合物以及它们在制造用于在温血动物（如人）中产生抗癌效果的药物中的使用。
• MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS
  申请人：Nishida Hidemitsu

  公开号：US20110059958A1

  公开（公告）日：2011-03-10

  The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明提供了如下式（I）所描述的化合物，或其药学上可接受的盐或溶剂。本发明还提供了包含一种或多种所述化合物的制药组合物，并使用该化合物治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。
• SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150232428A1

  公开（公告）日：2015-08-20

  The invention provides certain substituted phenyl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R cy , and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).

  本发明提供了公式(I)或其药学上可接受的盐的某些取代苯基化合物，其中R1、R2、R3、R4、Rcy和t如本文中所定义。本发明还提供了包括这些化合物的制药组合物以及使用这些化合物治疗Spleen Tyrosine Kinase（Syk）介导的疾病或病症的方法。